Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | PTGFR | P43088 | 1/20 | 0.38 |
| ▸ | EIF4EBP1 | Q13541 | 10/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6602537 | 0.95 | PTGFR (0.39) | PTPN11PTGFREIF4EBP1PTGER1CYP2C9 | |
| SCHEMBL6603696 | 0.93 | PTPN11 (0.41) | PTPN11PTGFREIF4EBP1PTGER1PPARG | |
| SCHEMBL6606279 | 0.92 | PLAU (0.38) | KMT2ARXFP1 | |
| SCHEMBL6602174 | 0.91 | PTGFR (0.38) | PTPN11PTGFRPPARAKMT2ARXFP1 | |
| SCHEMBL6605955 | 0.88 | PTPN11 (0.40) | PTPN11PTGFREIF4EBP1PTGER1PPARG | |
| SCHEMBL6600752 | 0.88 | PLAU (0.39) | CYP2C9KMT2ARXFP1 | |
| SCHEMBL6601619 | 0.86 | PTGFR (0.39) | PTPN11PTGFRPTGER1CYP2C9KMT2A | |
| SCHEMBL6604292 | 0.86 | RXFP1 (0.36) | PTGFRPTGER1KMT2ARXFP1 | |
| SCHEMBL6604839 | 0.85 | NCEH1 (0.37) | KMT2ARXFP1 | |
| SCHEMBL6602601 | 0.85 | PLAU (0.39) | KMT2ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180891-A1 | Pyrazole derivatives useful in the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-09-16 | — | — | US | disclosed |
| EP-1432689-A1 | PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | Bayer Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003027074-A1 | PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180891-A1 | Pyrazole derivatives useful in the treatment of hyper-proliferative disorders | MKI67, CDK4, FLT4 | PTPN11 3094/4885PTGFR 902/4885EIF4EBP1 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.